

Resource Summary Report

Generated by ASWG on Aug 10, 2026

CD34-PE-Vio770, human

RRID:AB_2660374

Type: Antibody

Proper Citation

Miltenyi Biotec Cat# 130-096-740, RRID:AB_2660374

Antibody Information

URL: http://antibodyregistry.org/AB_2660374

Proper Citation: Miltenyi Biotec Cat# 130-096-740, RRID:AB_2660374

Target Antigen: CD34

Host Organism: mouse

Clonality: monoclonal

Comments: Discontinued: 11-2018; Target Distribution bone marrow, cancer stem cells, CNS cells, dendritic cells, endothelial cells, fibroblasts, hematopoietic stem cells, liver, mast cells, osteoblasts; target type CD markers; tested applications MACS Flow Cytometry; quantity:

Info: This product is discontinued and reformatted to a higher concentration for optimized use in multicolor flow cytometry panels. The replacement product cat # is 130-113-180. (RRID:AB_2733226).

Antibody Name: CD34-PE-Vio770, human

Description: This monoclonal targets CD34

Target Organism: human

Clone ID: AC136

Antibody ID: AB_2660374

Vendor: Miltenyi Biotec

Catalog Number: 130-096-740

Record Creation Time: 20250819T205538+0000

Record Last Update: 20250819T211635+0000

Ratings and Alerts

No rating or validation information has been found for CD34-PE-Vio770, human.

Warning: Discontinued: 2021

Discontinued: 11-2018; Target Distribution bone marrow, cancer stem cells, CNS cells, dendritic cells, endothelial cells, fibroblasts, hematopoietic stem cells, liver, mast cells, osteoblasts; target type CD markers; tested applications MACS Flow Cytometry; quantity: Info: This product is discontinued and reformatted to a higher concentration for optimized use in multicolor flow cytometry panels. The replacement product cat # is 130-113-180. (RRID:AB_2733226).

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 1 mentions in open access literature.

Listed below are recent publications. The full list is available at [ASWG](#) .

Cortés-López M, et al. (2023) Single-cell multi-omics defines the cell-type-specific impact of splicing aberrations in human hematopoietic clonal outgrowths. Cell stem cell, 30(9), 1262.